Same modality, two worlds in the Q3 reports: Nuotai posted revenue +14.4% but net profit -24.6%, with gross margin down 10.85 points in a year; WuXi AppTec's TIDES grew 46.9% with full-year guidance raised to ~RMB 16.7bn. This is not a demand gap but a business-model gap - peptide API (selling molecules) and peptide CDMO services (selling capabilities) are diverging into two businesses. Using Q3 data, this piece maps the divide and asks: can CDMOs escape the API cycle's fatalism?

Put two Q3 reports side by side and a stark contrast emerges. Nuotai Biotech (ST Nuotai): first-nine-month revenue RMB 1.75bn, +14.43%; net profit RMB 335m, -24.61%; gross margin 57.61%, down 10.85 points from 68.46% a year earlier. WuXi AppTec: TIDES (peptides and oligonucleotides) nine-month revenue RMB 11.52bn, +46.9%, full-year guidance raised to about RMB 16.7bn (+47%), client count +37%, molecule count +86%. Both sit at the center of the GLP-1 wave, yet one is heading down and the other up. The reason is not demand - it is business model.

1. Nuotai's bind: API is a cyclical business

Nuotai's 'growth without profit' is not an operational failure but another act in the API cycle. The company described the curve plainly in an investor-relations session: in 2023-2024, GLP-1 peptide API was sold mainly for generic makers' R&D and registration, with small purchase volumes, a small industry footprint, and high prices and margins. From 2025, sales shifted to global commercial orders, industry capacity grew too fast, and supply-demand competition intensified. According to its regulatory query reply, capacity was released en masse in 2025; combined with low-price competition, cost-down from mature processes, and sharp cuts in overseas downstream formulation prices, GLP-1 peptide API prices fell sharply from Q3 2025.

The data confirm the curve: semaglutide API quotes fell from about USD 900/g to USD 90-160/g; global suppliers expanded from single digits in 2023 to 40-plus, with over 30 in China alone; and by MedTrend's count nearly 250 Chinese drugmakers have entered GLP-1. The result is the classic 'shortage - rush in - glut - price collapse' sequence: Nuotai's volumes rose, but the price drop outran volume gains; high-margin commercial orders became scarcer and low-margin orders rose in mix, squeezing profit. Add impairments (RMB 91.9m in 2025, RMB 86.4m in H1 2026) and litigation provisions (RMB 43.1m), and the profit side worsened further.

2. WuXi's premium: CDMO is a capability business

Unlike selling molecules, WuXi TIDES sells R&D and manufacturing capability. Its revenue growth comes from expanding clients (+37%) and molecules (+86%), sitting on 3,863 small-molecule D&M pipeline projects, 103 commercial programs and 94 Phase III programs - later-stage projects carry higher per-program revenue, and once a client is onboarded early, it naturally scales to later stages as the molecule progresses, creating a 'grow with the molecule' compounding effect. The moat here is not any single molecule's price but integrated delivery from pre-clinical CMC to commercial formulation, plus a quality system repeatedly audited and certified by global majors.

Asymchem's Q3 offers a third coordinate: its emerging businesses (peptides, oligonucleotides, ADC payload-linkers) booked RMB 1.92bn, +50.20%, but gross margin was only 30.95%, well below small molecules' 47.97%. This shows 'selling capability' is not automatically high-margin - emerging businesses are in a capacity-ramp and mix-shift phase, with structurally lower margins. The company argues peptides and oligonucleotides carry higher barriers than small molecules, that global 'tickets' are scarce, and that supply will lag demand for years - which supports service premium durability, provided margins converge from 31% toward 40%.

Table 1 Q3 comparison of two businesses: peptide API vs peptide CDMO services (cxdmo.com)
DimensionPeptide API (selling molecules)Peptide CDMO services (selling capability)
RepresentativeNuotai Biotech (ST Nuotai)WuXi TIDES / Asymchem emerging businesses
Q3 performanceRevenue +14.43%, net profit -24.61%, margin 57.61% (-10.85pt)WuXi TIDES +46.9% (~RMB 16.7bn FY); Asymchem emerging +50.2%
Growth sourceCommercial order volumes (price war, volume for price)Clients +37%, molecules +86%; scaling with molecules to later stages
Pricing logicMoves with supply-demand cycle; semaglutide API USD 900→90-160/gCost-plus reasonable margin; certification and delivery set the premium
Core riskOvercapacity, price collapse, impairmentMargin ramp, capacity certification, Q4 delivery pressure
Sample companies have overlapping businesses (Nuotai also runs peptide CDMO; WuXi also has proprietary API); classification follows the dominant revenue model to illustrate the two logics.

3. The divide: product cyclicality vs service stickiness

The fundamental difference lies in revenue quality and predictability. API revenue is tied to a single molecule's price cycle: once capacity gluts, patents expire and generics pile in, price collapse is almost unavoidable - the fate of a commodity, regardless of how good the company is. CDMO service revenue is tied to client relationships and project pipelines: the further a molecule advances toward commercialization, the harder it is to switch suppliers (requiring a fresh tech transfer and regulatory filing), so revenue stickiness and visibility rise. WuXi TIDES' 'clients +37%, molecules +86%' is a more important signal than 'revenue +46.9%' precisely because the former previews a multi-year revenue reservoir.

But CDMOs are not immune. They have their own cycle - capacity arms races, supply-chain reshoring under Section 232 tariffs, and emerging-business margin ramps. Asymchem's 30.95% emerging-business margin is a reminder that service premiums are not automatic: they need lean operations, time, certified lines and commercial delivery records. The sturdiest players are those converting 'selling molecules' cycle exposure into 'selling capability' long-term contracts - Nuotai itself is doing this, shifting focus from single GLP-1 to GLP-1 plus oligonucleotides, with its Lianyungang ton-scale oligonucleotide API workshop commissioned in early 2026.

4. Conclusion: don't measure two peptide companies with one ruler

For investors and industry watchers, the practical implication is clear: evaluating a peptide company can no longer start with 'does it benefit from GLP-1?' but with what it actually sells along the chain. For API sellers, watch supply-demand, price curves and capacity-clearing signals; for service sellers, watch client counts, molecule counts, PPQ schedules and PAI approvals. Both can coexist within one company, but with different valuation logic, cycle positions and risk exposure. The Q3 reports have drawn this line sharply: same peptide, one a prisoner of the price war, the other a beneficiary of capability premium.

Peptide API sells molecules and cannot escape the 'shortage - glut - price collapse' cycle; peptide CDMO sells capability and rides out cycles through client stickiness and pipelines. Both benefit from GLP-1, but the two should not be valued with the same ruler.

cxdmo.com industry desk

FAQ

FAQ

Why is Nuotai's revenue rising while profit plunges?

Because GLP-1 peptide API moved from shortage to overcapacity and a price war: semaglutide API quotes fell from about USD 900/g to USD 90-160/g, so volume gains were outpaced by price declines; gross margin fell from 68.46% to 57.61% (-10.85pt), plus RMB 86.4m in impairments and RMB 43.1m in litigation provisions - a textbook 'growth without profit.'

Why can WuXi TIDES sustain high growth in the same peptide space?

Different model. WuXi sells R&D and manufacturing capability; revenue comes from clients +37% and molecules +86%, scaling naturally as molecules advance to later commercial stages - a 'grow with the molecule' compounding effect. Its moat is integrated delivery and a globally certified quality system, not any single molecule's price.

Can CDMO services fully escape the API cycle?

No - the cycle source just differs. CDMO cycles come from capacity arms races, Section 232 supply-chain reshoring, and emerging-business margin ramps - Asymchem's emerging margin of just 30.95% shows service premiums need lean operations and certification, not automatic. But versus single-molecule pricing, service revenue has higher stickiness and visibility.

How to read a company doing both API and CDMO?

Split the two businesses by revenue share and cycle position. For API, watch price curves and capacity clearing; for services, watch clients, molecules, PPQ schedules and PAI approvals. Nuotai is shifting from single GLP-1 to GLP-1 plus oligonucleotides and moving downstream into formulations to hedge API cyclicality - whether it succeeds still needs utilization and depreciation data to confirm.

This article is compiled from public reporting. Original source: Compiled from Q3 2026 reports of Nuotai Biotech, WuXi AppTec and Asymchem; Jiemian, Eastmoney, Chengdu Business Daily and related cxdmo.com coverage · For industry reference only; not investment advice.